Literature DB >> 24909175

A novel function of HER2/Neu in the activation of G2/M checkpoint in response to γ-irradiation.

Y Yan1, A L Hein1, P M Greer1, Z Wang1, R H Kolb1, S K Batra2, K H Cowan1.   

Abstract

In response to γ-irradiation (IR)-induced DNA damage, activation of cell cycle checkpoints results in cell cycle arrest, allowing time for DNA repair before cell cycle re-entry. Human cells contain G1 and G2 cell cycle checkpoints. While G1 checkpoint is defective in most cancer cells, commonly due to mutations and/or alterations in the key regulators of G1 checkpoint (for example, p53, cyclin D), G2 checkpoint is rarely impaired in cancer cells, which is important for cancer cell survival. G2 checkpoint activation involves activation of ataxia telangiectasia-mutated (ATM)/ATM- and rad3-related (ATR) signalings, which leads to the inhibition of Cdc2 kinase and subsequent G2/M cell cycle arrest. Previous studies from our laboratory show that G2 checkpoint activation following IR exposure of MCF-7 breast cancer cells is dependent on the activation of extracellular signal-regulated protein kinase 1 and 2 (ERK1/2) signaling. As HER receptor tyrosine kinases (RTKs), which have important roles in cell proliferation and survival, have been shown to activate ERK1/2 signaling in response to various stimuli, we investigated the role of HER RTKs in IR-induced G2/M checkpoint response in breast cancer cells. Results of the present studies indicate that IR exposure resulted in a striking increase in the phosphorylation of HER1, HER2, HER3 and HER4 in MCF-7 cells, indicative of activation of these proteins. Furthermore, specific inhibition of HER2 using an inhibitor, short hairpin RNA and dominant-negative mutant HER2 abolished IR-induced activation of ATM/ATR signaling, phosphorylation of Cdc2-Y15 and subsequent induction of G2/M arrest. Moreover, the inhibition of HER2 also abrogated IR-induced ERK1/2 phosphorylation. In contrast, inhibition of HER1 using specific inhibitors or decreasing expression of HER3 or HER4 using short hairpin RNAs did not block the induction of G2/M arrest following IR. These results suggest an important role of HER2 in the activation of G2/M checkpoint response following IR.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24909175      PMCID: PMC4362969          DOI: 10.1038/onc.2014.167

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  59 in total

Review 1.  EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review).

Authors:  Patrick M Navolanic; Linda S Steelman; James A McCubrey
Journal:  Int J Oncol       Date:  2003-02       Impact factor: 5.650

Review 2.  Phosphorylation of serine 10 in histone H3, what for?

Authors:  Claude Prigent; Stefan Dimitrov
Journal:  J Cell Sci       Date:  2003-09-15       Impact factor: 5.285

Review 3.  Cell-cycle checkpoints and cancer.

Authors:  Michael B Kastan; Jiri Bartek
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

4.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Authors:  Anirudh Prahallad; Chong Sun; Sidong Huang; Federica Di Nicolantonio; Ramon Salazar; Davide Zecchin; Roderick L Beijersbergen; Alberto Bardelli; René Bernards
Journal:  Nature       Date:  2012-01-26       Impact factor: 49.962

Review 5.  Current strategies in overcoming resistance of cancer cells to apoptosis melanoma as a model.

Authors:  Peter Hersey; L Zhuang; X D Zhang
Journal:  Int Rev Cytol       Date:  2006

6.  Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation.

Authors:  R K Schmidt-Ullrich; R B Mikkelsen; P Dent; D G Todd; K Valerie; B D Kavanagh; J N Contessa; W K Rorrer; P B Chen
Journal:  Oncogene       Date:  1997-09-04       Impact factor: 9.867

7.  EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts.

Authors:  Birgit Geoerger; Nathalie Gaspar; Paule Opolon; Jackie Morizet; Pauline Devanz; Yann Lecluse; Alexander Valent; Ludovic Lacroix; Jacques Grill; Gilles Vassal
Journal:  Int J Cancer       Date:  2008-07-01       Impact factor: 7.396

8.  Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.

Authors:  Jitesh P Jani; Richard S Finn; Mary Campbell; Kevin G Coleman; Richard D Connell; Nicolas Currier; Erling O Emerson; Eugenia Floyd; Shawn Harriman; John C Kath; Joel Morris; James D Moyer; Leslie R Pustilnik; Kristina Rafidi; Sherry Ralston; Ann Marie K Rossi; Stefanus J Steyn; Larry Wagner; Steven M Winter; Samit K Bhattacharya
Journal:  Cancer Res       Date:  2007-10-15       Impact factor: 12.701

9.  Hepatitis B virus X protein via the p38MAPK pathway induces E2F1 release and ATR kinase activation mediating p53 apoptosis.

Authors:  Wen-Horng Wang; Ronald L Hullinger; Ourania M Andrisani
Journal:  J Biol Chem       Date:  2008-07-07       Impact factor: 5.157

10.  ERK1/2 signaling plays an important role in topoisomerase II poison-induced G2/M checkpoint activation.

Authors:  Ryan H Kolb; Patrick M Greer; Phu T Cao; Kenneth H Cowan; Ying Yan
Journal:  PLoS One       Date:  2012-11-16       Impact factor: 3.240

View more
  16 in total

Review 1.  Thirty Years of HER3: From Basic Biology to Therapeutic Interventions.

Authors:  Heidi M Haikala; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2021-02-19       Impact factor: 12.531

2.  Induction of G2M Arrest by Flavokawain A, a Kava Chalcone, Increases the Responsiveness of HER2-Overexpressing Breast Cancer Cells to Herceptin.

Authors:  Danielle D Jandial; Lauren S Krill; Lixia Chen; Chunli Wu; Yu Ke; Jun Xie; Bang H Hoang; Xiaolin Zi
Journal:  Molecules       Date:  2017-03-14       Impact factor: 4.411

Review 3.  Radiation-induced signaling pathways that promote cancer cell survival (review).

Authors:  Ashley L Hein; Michel M Ouellette; Ying Yan
Journal:  Int J Oncol       Date:  2014-08-20       Impact factor: 5.650

4.  A novel function of hepatocyte growth factor in the activation of checkpoint kinase 1 phosphorylation in colon cancer cells.

Authors:  Na Song; Xiaofang Che; Lu Xu; Jinglei Qu; Huachuan Zheng; Kezuo Hou; Xiujuan Qu; Yunpeng Liu
Journal:  Mol Cell Biochem       Date:  2017-06-01       Impact factor: 3.396

5.  Silencing human epidermal growth factor receptor-3 radiosensitizes human luminal A breast cancer cells.

Authors:  Guofeng He; Xiaoke Di; Jingjing Yan; Caiqiang Zhu; Xinchen Sun; Shu Zhang
Journal:  Cancer Sci       Date:  2018-10-22       Impact factor: 6.716

6.  Newly Synthesized Doxorubicin Complexes with Selected Metals-Synthesis, Structure and Anti-Breast Cancer Activity.

Authors:  Agata Jabłońska-Trypuć; Grzegorz Świderski; Rafał Krętowski; Włodzimierz Lewandowski
Journal:  Molecules       Date:  2017-07-04       Impact factor: 4.411

7.  Celastrol mediates autophagy and apoptosis via the ROS/JNK and Akt/mTOR signaling pathways in glioma cells.

Authors:  Xihong Liu; Peiyuan Zhao; Xiujuan Wang; Lei Wang; Yingjun Zhu; Yadi Song; Wei Gao
Journal:  J Exp Clin Cancer Res       Date:  2019-05-03

8.  RAC1 Involves in the Radioresistance by Mediating Epithelial-Mesenchymal Transition in Lung Cancer.

Authors:  Shiming Tan; Pin Yi; Heran Wang; Longzheng Xia; Yaqian Han; Hui Wang; Biao Zeng; Lu Tang; Qing Pan; Yutong Tian; Shan Rao; Linda Oyang; Jiaxin Liang; Jinguan Lin; Min Su; Yingrui Shi; Qianjin Liao; Yujuan Zhou
Journal:  Front Oncol       Date:  2020-04-28       Impact factor: 6.244

9.  Acetylation of MORC2 by NAT10 regulates cell-cycle checkpoint control and resistance to DNA-damaging chemotherapy and radiotherapy in breast cancer.

Authors:  Hong-Yi Liu; Ying-Ying Liu; Fan Yang; Lin Zhang; Fang-Lin Zhang; Xin Hu; Zhi-Min Shao; Da-Qiang Li
Journal:  Nucleic Acids Res       Date:  2020-04-17       Impact factor: 16.971

10.  Inhibition of ERK1/2 or AKT Activity Equally Enhances Radiation Sensitization in B16F10 Cells.

Authors:  Bhuvanesh Sukhlal Kalal; Faraz Fathima; Vinitha Ramanath Pai; Ganesh Sanjeev; Chilakapati Murali Krishna; Dinesh Upadhya
Journal:  World J Oncol       Date:  2018-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.